Hoda Azizi; Farahzad Jabbari; Mahmud Shabestari; Maryam Hashemian
Volume 19, Issue 3 , September and October 2012, , Pages 206-216
Abstract
Background: Given the high prevalence and high mortality of cardiovascular disease, special attention should be paid to its treatment. Currently, the main treatment for ST-elevation myocardial infarction is restoring blood flow by dissolving the clot. In addition to this basic treatment, several pharmacologic ...
Read More
Background: Given the high prevalence and high mortality of cardiovascular disease, special attention should be paid to its treatment. Currently, the main treatment for ST-elevation myocardial infarction is restoring blood flow by dissolving the clot. In addition to this basic treatment, several pharmacologic agents have been studied during the past years. In this paper, clinical trials about glucose-insulin-potassium are discussed in addition to adjuvant treatment which has been suggested in recent years. Materials and Methods: All studies published in journals or presented at scientific conferences were searched in Elsevier, PubMed, Cochrane, and SID databases using relevant keywords. After quality control, eligible articles were included in the study. Results: The results of this review article showed that studies on the effects of glucose-insulin-potassium treatment on mortality, cardiac enzyme levels, left ventricular ejection fraction, ST resolution, and inflammatory and oxidative biomarkers have been conflicting. But, generally, evidence from newer studies conducted on larger numbers of patients has shown ineffectiveness of glucose-insulin-potassium therapy. Conclusion: Currently, glucose-insulin-potassium therapy should not be recommended as an adjunct to thrombolytic therapy.
AliReza Vakili; Maryam Hashemiyan; Arash Akaberi
Volume 17, Issue 2 , July and August 2010, , Pages 67-73
Abstract
Background and Purpose: Some researchers believe that the treatment with glucose–insulin–potassium (GIK) in ST segment elevation myocardial infarction (STEMI) can reduce the mortality rate. Others, however, contradict this view. Therefore, the present study was designed to evaluate the clinical and ...
Read More
Background and Purpose: Some researchers believe that the treatment with glucose–insulin–potassium (GIK) in ST segment elevation myocardial infarction (STEMI) can reduce the mortality rate. Others, however, contradict this view. Therefore, the present study was designed to evaluate the clinical and paraclinical effects of GIK in STEMI patients. Methods: This triple blind clinical trial was conducted from September 2008 to July 2009 on 72 STEMI patients in the CCU of Vasei Hospital in Sabzevar, Iran. They were assigned through block randomization into standard care or additional GIK infusion (25% glucose, 50 IU of soluble insulin per liter, and 80 mmol of potassium chloride per liter at 1.5 ml/kg/hour). They were assessed for the number of MACEs (death, reinfarction and serious arrhythmias), plasma concentrations of cardiac enzymes (CK, CK-MB), and left ventricular ejection fraction. The statistical analysis was conducted in SPSS 11.5 using Fisher’s exact test, t-test and repeated measurement. P
Masood Ebrahimi; Maryam Hashemian
Volume 17, Issue 1 , March and April 2010, , Pages 63-66
Abstract
Background and Purpose: Crimean Congo fever was first characterized in 1944 in the Crimean peninsula and then in 1956 in Congo. Their sameness was recognized after long investigation in the two continents, and was labeled as Crimean Congo Hemorrhagic Fever or CCHF. It is one of the hemorrhagic fevers, ...
Read More
Background and Purpose: Crimean Congo fever was first characterized in 1944 in the Crimean peninsula and then in 1956 in Congo. Their sameness was recognized after long investigation in the two continents, and was labeled as Crimean Congo Hemorrhagic Fever or CCHF. It is one of the hemorrhagic fevers, which manifests as a sudden onset of high fever, chills; severe headache, dizziness, back and abdominal pain after a short incubation period, CCHF is characterized by a sudden onset of high fever, chills and myalgia, and turns into hemorrhagic phase after five days. The Patient: The patient was a 15-year-old boy treated for brucellosis from 15 days ago and was admitted because of fever, headache and vomiting diagnosed as brucella meningitis. Because of thrombocytopenia, sporadic petecia and epistaxi, diagnosis of CCHF was suspected and reported as positive according to RT-PCR. Conclusion: Likelihood of CCHF in animal husbandry occupations is possible, and since its symptoms are similar to brucellosis, its diagnosis must be considered together with brucellosis.